Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712737 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
EnterprisewideAdd to Basket
EnterprisewideAdd to Basket
Electronic (Online Access)Add to Basket
Hard CopyAdd to Basket
Electronic (PDF)Add to Basket
Live Chat Live Help Software for Website

The Pharmaceutical Market: Netherlands

Espicom Business Intelligence Ltd, Oct 2011, Pages: 82


  Description  
   Table of Contents   
   Companies Mentioned   
    
    
     
  Enquire before Buying   
  Send to a Friend   

THE PHARMACEUTICAL MARKET: THE NETHERLANDS - REVIEW

The Dutch government has introduced a mandatory health insurance scheme, which replaced the previous two-tier system and provides basic health insurance cover for acute care services, with a separate scheme for long-term medical care. The reforms have given health insurers a more prominent role in determining the level of Dutch healthcare spending and this has given rise to an even more competitive market environment for suppliers, as evidenced by the move towards a preferred supplier system.

Following Schering-Plough’s merger with Merck, the company announced it was to close three R&D sites in the Netherlands, leading to the loss of around 2,000 jobs. However, in May 2011, MSD reported that it had decided to reorganise its operations in Oss and that almost 500 research jobs would remain at the plant to focus on medicines for developed markets. The closure at Boxmeer went ahead as planned with the loss of around 35 jobs. MSD is still looking into an alternative solution for the facility in Scaijk.

In February 2011, the Ministry of Health, Welfare and Sport (VWS) announced it was putting the production facility of the Netherlands Vaccine Institute (NVI) in Bilthoven up for sale. The Institute had a long history of supplying vaccines to the Dutch population, but a change in policy means that this will now be carried out by the private sector. The sale of the Institute marks the end of one of the last remaining public vaccine facilities around the world.

Many new biologic drugs have been registered in the Dutch pharmaceutical market in the past few years. There are a number of biopharmaceutical companies present in the Netherlands. In February 2011, Johnson & Johnson completed its acquisition of Crucell, but the company will continue to operate independently. In June 2010, Fornix Biosciences sold its allergy division to ALK-Abelló.

ENHANCED STRATEGIC INTELLIGENCE

These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.



Customers who bought this item also bought

The Pharmaceutical Market: Canada

The Pharmaceutical Market: Japan

The Pharmaceutical Market: Pakistan

The Pharmaceutical Market: Ireland

The Pharmaceutical Market: Ukraine

The Pharmaceutical Market: Indonesia

The Pharmaceutical Market: India

The Pharmaceutical Market: Thailand

The Pharmaceutical Market: Saudi Arabia

The Pharmaceutical Market: Latvia



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds